Small cell lung cancer · 6 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
VMV/VAC Variant #01 | — | R 2 551 | 21d | — | — | ~2 | ~R 5 102 indirect | — |
Carboplatin and Etoposide (CE) Variant #01 | — | R 2 301 | 28d | 4.4 mo | 10.6 mo | 7 | R 16 108 PFS proxy | 16 |
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | 5.0 mo | 10.2 mo | 4 | R 7 277 PFS proxy | 10 |
CAV/PE Variant #02 | — | R 1 478 | 21d | — | — | ~3 | ~R 4 435 indirect | — |
CAV Variant #06 | — | R 865 | 21d | — | ~7.6 mo | ~6 | ~R 5 188 PFS proxy · indirect | 1 |
MACC Variant #01 Partial | — | R 605 | 21d | — | — | ~2 | ~R 1 209 indirect | — |
6 of 6 regimens shown